Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
An in-depth look at Eloxatin (oxaliplatin) dosage, administration, and its role in treating colorectal cancer, including combination therapy and potential side effects, for Indian patients.
Eloxatin, with the active ingredient oxaliplatin, is a crucial chemotherapy drug used in the treatment of certain types of colorectal cancer in adults. It belongs to a class of drugs known as chemotherapy agents, which work by targeting and destroying cancer cells. This article provides a comprehensive overview of Eloxatin dosage, its administration, and its role in combination therapy for colorectal cancer, tailored for an Indian audience seeking clear and practical information.
Eloxatin's active component, oxaliplatin, is a platinum-based chemotherapy drug. It functions by creating cross-links in the DNA of cancer cells, which disrupts their ability to replicate and ultimately leads to their death. This mechanism is vital in combating the uncontrolled growth characteristic of cancer.
Eloxatin is prescribed for adults diagnosed with specific forms of colorectal cancer, including:
It is typically administered as part of a multi-drug chemotherapy regimen.
The dosage of Eloxatin is highly individualized and is determined by a healthcare professional based on several factors, most importantly the patient's Body Surface Area (BSA). BSA is a measure calculated in square meters (m²) using a person's height and weight. This personalized approach ensures optimal efficacy while minimizing potential side effects.
Eloxatin is available as a liquid solution in single-dose vials. The concentration is 5 mg of oxaliplatin per milliliter of liquid solution (5 mg/mL).
For patients with stage 3 colon cancer who have undergone surgery, the usual Eloxatin dosage is calculated at 85 mg per square meter of Body Surface Area (85 mg/m²). This dosage is administered on day 1 of a 14-day treatment cycle. Treatment may continue for up to 12 cycles, which typically spans about 6 months.
In cases of advanced colorectal cancer, the dosage calculation is similar, with the standard recommendation being 85 mg/m². This is also given on day 1 of a 14-day treatment cycle. Unlike stage 3 colon cancer, there is no predetermined limit to the number of treatment cycles for advanced colorectal cancer. Patients may continue to receive Eloxatin as long as it remains effective in managing their condition.
Eloxatin is administered intravenously (IV), meaning it is injected into a vein over a period of time. This procedure is performed by a qualified healthcare professional at a hospital, an infusion center, or another designated medical facility. The infusion typically takes approximately 2 hours.
Eloxatin is rarely used as a standalone treatment for colorectal cancer. It is most commonly administered as part of a combination chemotherapy regimen that includes two other drugs: leucovorin and fluorouracil. This combination approach is often more effective in fighting cancer cells.
On day 1 of a 14-day cycle, a patient will typically receive Eloxatin, leucovorin, and fluorouracil. On day 2 of the cycle, leucovorin and fluorouracil are administered again.
Like all chemotherapy drugs, Eloxatin can cause side effects. It is important for patients to discuss any concerns with their doctor. Common side effects may include:
Prompt reporting of any new or worsening symptoms to the healthcare team is crucial for managing side effects effectively.
It is essential to consult with your oncologist or healthcare provider if you are considering Eloxatin treatment or have been prescribed it. They will:
Do not attempt to self-administer or adjust Eloxatin dosage. All treatments should be managed under the supervision of qualified medical professionals.
The active ingredient in Eloxatin is oxaliplatin.
Eloxatin is given as an intravenous (IV) infusion by a healthcare professional.
No, Eloxatin infusions must be administered in a medical setting like a hospital or infusion center by trained personnel.
BSA is a measure of a person's total surface area, calculated using height and weight. It is used to personalize drug dosages, ensuring that the amount of medication is appropriate for the individual's body size, which helps optimize effectiveness and minimize toxicity.
Eloxatin is commonly given with leucovorin and fluorouracil as part of a chemotherapy regimen.
You should immediately report any side effects to your doctor or healthcare team. They can provide guidance on managing these effects and may adjust your treatment if necessary.
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.
This section adds practical context and preventive advice to help readers make informed healthcare decisions. It is important to verify symptoms early, consult qualified doctors, and avoid self-medication for persistent health issues.
Maintaining healthy routines, following prescribed treatment plans, and attending regular checkups can improve outcomes. If symptoms worsen or red-flag signs appear, immediate medical evaluation is recommended.
Track symptoms and duration.
Follow diagnosis and treatment from a licensed practitioner.
Review medication side effects with your doctor.
Seek urgent care for severe warning signs.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026
Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026